Home › Brain Tumors › NCT06132685
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
Post-Operative Dosing of Steroids Post Craniotomy for Brain Tumor (PODS)
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Patients with radiographic findings consistent with either HGG, LGG, Meningioma, or brain metastasis * Age equal to or above 18 Exclusion Criteria: * Known hypothalamic-pituitary-adrenal (HPA) axis dysfunction * Tumor causing compression of the sella or pituitary dysfunction * Known immunodeficiency - including but not limited to severe combined immunodeficiency (SCID), common variable immunodeficiency (CVID), lymphocytopenia * Taking immunosuppressive drugs - including but not limited to methotrexate, mycophenolate, rapamycin, tacrolimus, adalimumab, infliximab. Greater than two weeks of recent daily corticosteroid use or the use of corticosteroids equivalent to \> 85 mg of dexamethasone in the last month * Current lymphoma or leukemia * History of solid organ transplant * Minors \< 18 * Pregnant women * History of cerebrovascular accident leading to neurologic deficit
About the study
This phase II trial tests the effect of decreasing (tapering) doses of dexamethasone on steroid side effects in patients after surgery to remove (craniotomy) a brain tumor. Steroids are the gold standard post-surgery treatment to reduce swelling (edema) at the surgical site to reduce neurological symptoms. Although, corticosteroids reduce edema, they have side effects including high blood sugar, high blood pressure, and can impair wound healing. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response. It also works to treat other conditions by reducing swelling and redness. Tapering doses dexamethasone may decrease steroid side effects without increasing the risk of edema in patients with brain tumors after a craniotomy.
What is being tested
- Biospecimen Collection (procedure)
- Computed Tomography (procedure)
- Dexamethasone (drug)
- Magnetic Resonance Imaging (procedure)
- Questionnaire Administration (other)
Sponsor: Emory University · Participants: 200 · Started: Jan 9, 2025
Contact the study team
- Kimberly Hoang, MD · Phone: 404-778-5770
Official record on ClinicalTrials.gov — NCT06132685
Locations in the U.S.
| Georgia | Emory University Hospital/Winship Cancer Institute, Atlanta |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.